Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 14Gastrointestinal 8Genitourinary 4Head & Neck 3Sarcoma 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Endocrine 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Osteonecrosis 1Osteomyelitis 1Chondrosarcoma 1Bone Neoplasms 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ferrosoferric Oxide × Sarcoma × Clear all
NCT01336803 2023-12-27

Osteosarcoma

Stanford University

Phase 2 Completed
32 enrolled 11 charts
Sarcoma

Bone Neoplasms, Chondrosarcoma, Osteomyelitis, Osteonecrosis, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT01663090 2020-10-19

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Dana-Farber Cancer Institute

Phase NA Withdrawn
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡